DR6/TNFRSF21 Antibody Blocking Peptide

Product Discontinued

DR6/TNFRSF21 Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 15 amino acids of human DR6.

  Source: Synthetic

  (Accession #: AF068868)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: TNFRSF21
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-76463.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for DR6/TNFRSF21 Antibody Blocking Peptide

• BM-018
• CD358 antigen
• CD358
• Death receptor 6
• DR6
• DR6TNFR-related death receptor 6
• MGC31965
• TNFRSF21
• tumor necrosis factor receptor superfamily member 21
• tumor necrosis factor receptor superfamily, member 21

Background

Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. Several novel death receptors including DR3, DR4, and DR5 were recently identified. A new death domain containing receptor in the TNFR family was cloned recently and termed DR6 for death receptor 6. Like TNFR1, DR6 interacts with death domain containing adapter molecule TRADD. Overexpression of DR6 induces apoptosis and activates NF-kB and JNK. DR6 is widely expressed inhuman tissues and cell lines. The ligand for DR6 hasnot been identified.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: TNFRSF21